Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophy
CRS Belder, D Boche, JAR Nicoll… - The Lancet …, 2024 - thelancet.com
Progressive cerebral volume loss on MRI is a hallmark of Alzheimer's disease and has been
widely used as an outcome measure in clinical trials, with the prediction that disease …
widely used as an outcome measure in clinical trials, with the prediction that disease …
Effect of apolipoprotein genotype and educational attainment on cognitive function in autosomal dominant Alzheimer's disease
S Langella, NG Barksdale, D Vasquez… - Nature …, 2023 - nature.com
Autosomal dominant Alzheimer's disease (ADAD) is genetically determined, but variability in
age of symptom onset suggests additional factors may influence cognitive trajectories …
age of symptom onset suggests additional factors may influence cognitive trajectories …
White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer's disease that emerge prior to dementia
D Schoemaker, MC Zanon Zotin, K Chen… - Alzheimer's Research & …, 2022 - Springer
Background To promote the development of effective therapies, there is an important need
to characterize the full spectrum of neuropathological changes associated with Alzheimer's …
to characterize the full spectrum of neuropathological changes associated with Alzheimer's …
Basal forebrain volume and metabolism in carriers of the Colombian mutation for autosomal dominant Alzheimer's disease
We aimed to study atrophy and glucose metabolism of the cholinergic basal forebrain in non-
demented mutation carriers for autosomal dominant Alzheimer's disease (ADAD). We …
demented mutation carriers for autosomal dominant Alzheimer's disease (ADAD). We …
Cholinergic-like neurons and cerebral spheroids bearing the PSEN1 p. Ile416Thr variant mirror Alzheimer's disease neuropathology
N Gomez-Sequeda, M Mendivil-Perez… - Scientific Reports, 2023 - nature.com
Familial Alzheimer's disease (FAD) is a complex neurodegenerative disorder for which there
are no therapeutics to date. Several mutations in presenilin 1 (PSEN 1), which is the catalytic …
are no therapeutics to date. Several mutations in presenilin 1 (PSEN 1), which is the catalytic …
Metabolite signature of Alzheimer's disease in adults with Down syndrome
Objective The purpose of this study was to examine the Alzheimer's disease metabolite
signature through magnetic resonance spectroscopy in adults with Down syndrome and its …
signature through magnetic resonance spectroscopy in adults with Down syndrome and its …
[PDF][PDF] INSTITUTO DE NEUROCIENCIASXX
RFF en la Expresión, OP de la Mutación… - riudg.udg.mx
La Organización Mundial de la Salud (2018) reportó que, a nivel mundial, la enfermedad de
Alzheimer (EA) afecta a aproximadamente 50 millones de personas y estima que la cifra …
Alzheimer (EA) afecta a aproximadamente 50 millones de personas y estima que la cifra …